U.S. Online Retail and Ecommerce Stock News

In late April 2026, Benchmark Electronics reported first-quarter 2026 results showing sales of US$677.28 million and net income of US$13.02 million, while issuing second-quarter revenue guidance of US$700 million to US$740 million. The company also raised its full-year 2026 revenue growth outlook to 9%–10%, underscoring management’s confidence in momentum across medical, semiconductor capital equipment, and advanced computing and communications end markets. We’ll now consider how the...

PPL Corporation is scheduled to report its March 2026 quarter earnings on May 8, 2026, with analysts previously expecting a year-over-year increase and a positive Earnings ESP, while its Kentucky utilities are working with X-energy to evaluate Xe-100 small modular nuclear reactors as a potential clean, reliable power source. This combination of anticipated earnings strength and early-stage nuclear collaboration underscores how PPL is increasingly aligning its regulated utility footprint with...

Edesa Biotech, Inc. ( NASDAQ:EDSA ) insiders who purchased shares in the last 12 months were richly rewarded last week...

Syndax Pharmaceuticals, Inc. ( NASDAQ:SNDX ) shareholders are probably feeling a little disappointed, since its shares...

We feel now is a pretty good time to analyse AmpliTech Group, Inc.'s ( NASDAQ:AMPG ) business as it appears the company...

While L.B. Foster Company ( NASDAQ:FSTR ) shareholders have had a good week with the stock up 15%, insiders can't say...

SiTime (SITM) has put timing technology back in the spotlight with its Elite 2 Super-TCXO launch, a chip aimed at tightening time synchronization in AI data centers and tackling GPU efficiency issues. See our latest analysis for SiTime. The Elite 2 Super-TCXO announcement comes after a period of strong momentum, with a 30 day share price return of 62.71% and a 1 year total shareholder return of 241.67%. This suggests that expectations and perceived risk have shifted meaningfully. If you are...

UFP Technologies has reported its first-quarter 2026 results, with sales rising to US$154.2 million and net income edging up to US$17.5 million, alongside slightly higher basic and diluted earnings per share versus a year earlier. Beneath these headline figures, growth in medical sales, a pullback in non-medical revenue, and new Dominican Republic facilities highlight the company’s sharpening focus on MedTech and capacity to support areas such as robotic surgery and safe patient...

TransMedics Group (TMDX) has drawn fresh attention after agreeing to invest in Germany based PAD Aviation to build a dedicated organ transplant logistics network in Europe, extending its Organ Care System reach. See our latest analysis for TransMedics Group. The stock has recently given back ground, with a 1 week share price return of a 10.21% decline and a 3 month share price return of a 28.47% decline. This comes even as product launches in Canada and progress on organ preservation trials...

Recent sentiment around Alpha Metallurgical Resources (AMR) has shifted after analysts flagged an expected quarterly loss, slightly softer revenue and sharply lower earnings estimates over the past month, alongside a current Strong Sell rating. See our latest analysis for Alpha Metallurgical Resources. The share price has been under pressure in recent weeks, with a 30 day share price return of an 11.68% decline and a 90 day share price return of a 12.34% decline. However, the 1 year total...

Robert Half Inc. recently reported first-quarter 2026 results showing year-over-year declines in net income and diluted earnings per share from continuing operations, while also declaring a quarterly dividend of US$0.5900 per share payable on June 15, 2026, to shareholders of record on May 22, 2026. Alongside these results, the company issued second-quarter 2026 guidance pointing to lower adjusted revenues than the prior year, highlighting ongoing operational headwinds even as it maintains...

Earnings shock and governance changes put KE Holdings in focus KE Holdings (BEKE) has drawn fresh attention after reporting a sharp drop in net income to RMB432 million from RMB2,750 million, along with steep pressure in new home transaction services and rising concerns about China’s housing market recovery. See our latest analysis for KE Holdings. The stock’s recent 1 month share price return of 17.89% and 7 day gain of 8.92%, against a 1 year total shareholder return decline of 14.91% and a...

Tenable Holdings (TENB) is back in focus after first quarter 2026 earnings, where revenue and profitability were ahead of its own expectations and full year guidance for both metrics was raised. See our latest analysis for Tenable Holdings. Despite the upbeat earnings and raised guidance, Tenable’s recent share price performance has been mixed, with a 30 day share price return of 18.5% but a 1 year total shareholder return decline of 33.4%. This suggests that optimism is rebuilding from a...

Fulton Financial (FULT) is back in focus after the bank completed a $300 million fixed to floating rate subordinated notes offering. This refinancing move reshapes its capital structure and long term funding profile. See our latest analysis for Fulton Financial. These refinancing plans and the recent share buyback sit against a mixed price backdrop. The 1 month share price return is 3.26%, but there has been a 1 day decline of 1.94%. Meanwhile, the 1 year total shareholder return of 29.03%...

Rev8 launch puts Ouster’s technology shift in focus Ouster (OUST) has drawn fresh attention after launching its Rev8 OS digital lidar sensors, built on its new L4 Ouster Silicon and introducing native color lidar with up to double the prior range and resolution. With orders already open and shipments starting this quarter, the Rev8 family targets automotive, industrial, robotics, and smart infrastructure uses, giving investors a concrete product milestone to watch as adoption by major...

PureCycle Technologies (PCT) is back in focus after Plastic Ingenuity adopted its PureFive resin for coffee lid production, bringing recycled polypropylene into a high volume, food contact packaging use case. See our latest analysis for PureCycle Technologies. The Plastic Ingenuity deal arrives after a volatile stretch for PureCycle, with a 35.61% 1 month share price return offset by a 25.53% 3 month share price decline and a 17.88% year to date share price fall. At the same time, the 1 year...

Twist Bioscience recently reported past second-quarter 2026 results, with sales rising to US$110.72 million from US$92.79 million a year earlier, while net loss widened to US$44.02 million and loss per share increased to US$0.71. Alongside earnings, Twist launched its Complex Genes offering, a step that materially broadens its ability to synthesize highly engineered, difficult-to-manufacture DNA sequences for advanced therapeutics and AI-driven drug discovery. Next, we’ll examine how the...

NVR (NVR) stock is back in focus after first quarter 2026 results showed lower profit and revenue, weaker homebuilding margins, and a drop in settlements, with earnings missing analyst expectations and pressuring sentiment. See our latest analysis for NVR. The weaker first quarter results and earnings miss have gone hand in hand with a 23.66% 90 day share price return decline and a 16.17% fall in 1 year total shareholder return, suggesting momentum has cooled after a modest 3 year gain. If...

In late April 2026, Constellium SE reported first‑quarter sales of US$2.46 billion and net income of US$199 million, with earnings per share from continuing operations rising sharply year on year and record Adjusted EBITDA prompting higher full‑year 2026 guidance and a new US$300 million share repurchase program. Alongside this strong start to 2026, Constellium secured a multi‑year aluminum extrusions supply agreement with Airbus and saw mixed insider activity, combining sizeable share sales...

IMAX (IMAX) surprised the market with first quarter earnings per share above analyst expectations, even as revenue softened. The company also reaffirmed its guidance for record 2026 box office and outlined early second quarter strength. See our latest analysis for IMAX. The latest earnings beat and reaffirmed box office guidance come as the stock has cooled in the short term, with a 1-month share price return of a 12.19% decline and a year-to-date share price return of a 2.17% decline. At the...

Cisco Systems (CSCO) has drawn fresh attention after unveiling its Universal Quantum Switch, a research prototype designed to route and convert quantum information across major encoding methods at room temperature on standard telecom fiber. See our latest analysis for Cisco Systems. That quantum networking announcement comes at a time when momentum in Cisco’s stock has clearly picked up, with a 30 day share price return of 17.22% and a 1 year total shareholder return of 59.75% reinforcing a...

Tennant (TNC) is back in focus after Q1 2026 results showed sales of US$297.9 million and non-GAAP EPS ahead of analyst expectations, alongside a larger share repurchase capacity of up to 15%. See our latest analysis for Tennant. At a share price of US$81.95, Tennant has seen a 17.34% 1 month share price return and a 10.80% year to date share price return. The 1 year total shareholder return of 16.32% points to building momentum as investors weigh Q1 earnings, the expanded buyback capacity...

Analyst Concerns and Dividend Move Put Tencent Music in Focus Recent analyst downgrades and slightly reduced fair value estimates have pushed Tencent Music Entertainment Group (TME) into the spotlight, as competition and earnings visibility stay front of mind for investors. At the same time, the company’s ordinary annual cash dividend of US$0.12 per share for 2025, with an ex dividend date of 1 April 2026, offers a degree of income continuity that some shareholders may welcome. See our latest...

In late April 2026, Nuvalent announced a multi-year collaboration with Guardant Health to use Guardant’s Infinity tissue and liquid biopsy platform to support clinical development, potential companion diagnostics, and future global commercialization of Nuvalent’s oncology pipeline. This partnership reinforces how precision diagnostics are becoming integral to drug development, tying Guardant’s testing capabilities directly to emerging targeted cancer therapies and potential regulatory...